Buse, John B.
Bethel, M. Angelyn
Green, Jennifer B.
Stevens, Susanna R.
Lokhnygina, Yuliya
Aschner, Pablo
Grado, Carlos Raffo
Tankova, Tsvetalina
Wainstein, Julio
Josse, Robert
Lachin, John M.
Engel, Samuel S.
Patel, Keyur
Peterson, Eric D.
Holman, Rury R.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
https://doi.org/10.1186/s12933-023-01802-x
Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
https://doi.org/10.2337/dc20-2806
Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?
https://doi.org/10.1016/j.clinthera.2014.10.009
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
https://doi.org/10.2337/dc20-2018
Pancreatic Safety of Sitagliptin in the TECOS Study
https://doi.org/10.2337/dc15-2780
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
https://doi.org/10.1016/s0140-6736(12)60691-6
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
https://doi.org/10.1186/s12933-019-0921-2
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial (Results)
https://doi.org/10.2337/dc17-1091
Diabetes, incretin hormones and cardioprotection
https://doi.org/10.1136/heartjnl-2012-303242
Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype
https://doi.org/10.2337/dc17-1778
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
https://doi.org/10.1186/s12933-023-01802-x
Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
https://doi.org/10.2337/dc20-2806
Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?
https://doi.org/10.1016/j.clinthera.2014.10.009
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
https://doi.org/10.2337/dc20-2018
Pancreatic Safety of Sitagliptin in the TECOS Study
https://doi.org/10.2337/dc15-2780
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
https://doi.org/10.1016/s0140-6736(12)60691-6
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
https://doi.org/10.1186/s12933-019-0921-2
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial (Results)
https://doi.org/10.2337/dc17-1091
Diabetes, incretin hormones and cardioprotection
https://doi.org/10.1136/heartjnl-2012-303242
Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype
https://doi.org/10.2337/dc17-1778
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Funding for this research was provided by:
Merck & Co., Inc